New Guidance Puts PBM Transparency Lawsuit in Limbo

Mere days after the top PBM trade group filed suit against a regulation requiring PBMs to report historical net prices of prescription drugs, the Biden administration issued guidance that effectively says that provision won’t be enforced anytime soon.

Still, it’s not yet certain what the Pharmaceutical Care Management Association (PCMA) or the U.S. Chamber of Commerce — which filed a similar suit against the so-called “transparency in coverage” rule — plan to do regarding their litigation. And one health plan trade group wants the administration to do more to address its concerns about the price transparency regulation.

© 2023 MMIT
Leslie Small

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

bills-and-pills
January 26

Medicare Enrollees May Still Face Affordability Issues After Part D Benefit Redesign

READ MORE
pills-in-hand
January 26

ICER Report Aims to Nudge Payers Toward Fairer Drug Coverage Policies

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
January 26

News Briefs: Lilly Alzheimer’s Drug Fails to Win Accelerated Approval

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today